

COMPANY PROFILE

Berlin-based NOXXON Pharma AG is a clinical stage biotechnology company focusing on the development of Spiegelmers® (also called L-aptamers) for the treatment of inflammatory diseases and haematological indications. NOXXON is in possession of a broad patent estate and a readily scalable GMP production process. In addition to its in-house programs NOXXON discovers and develops Spiegelmers in collaboration with partners from the pharmaceutical industry, including Eli Lilly and Hoffmann La-Roche. The business strategy of NOXXON is to broaden this range of collaborations through co-development and licensing agreements for the proprietary clinical and pre-clinical products as well as technology-based multi-target partnerships. Currently the company has two compounds in clinical development. The declared goal of NOXXON is to establish its oligonucleotide-based drug discovery platform (Spiegelmers) as the leading 'scaffold' technology to create new chemical entities with superior properties.

RECENT NEWS

- 07/2010: NOXXON to initiate phase Ib clinical trial of MCP-1 inhibitor NOX-E36
- 06/2010: NOXXON announces management changes
- 05/2010: NOXXON raises €33 million in Series D Round
- 05/2010: NOXXON appoints Dr. Aram Mangasarian as Chief Business Officer
- 05/2010: NOXXON announces the completion of the first-in-human clinical trial with NOX-A12

more news on www.noxxon.com

INTELLECTUAL PROPERTY

NOXXON has pursued an aggressive patent and licensing strategy making the Spiegelmer Technology one of the best protected drug discovery platforms in the industry. NOXXON's intellectual property (IP) comprises a) an exclusive license to the SELEX process for screening of nucleic acid libraries to make Spiegelmers for therapeutic applications, b) patents covering mirroring technologies, c) Spiegelmer modification patents that improve the substance class' versatility, and d) composition of matter patents for Spiegelmer products. The IP estate includes over 340 patents and patent applications, ensuring full freedom to operate for NOXXON and its partners.

STRATEGIC ALLIANCES

Eli Lilly and Company: Licensing and discovery partnership to develop novel therapies for the treatment of migraine.

F. Hoffmann-La Roche: R & D partnership to develop novel Spiegelmer therapeutics for the treatment of inflammatory diseases.

DEVELOPMENT MILESTONES 2009 - 2012

2009	2010	2011	2012
Start Phase I NOX-E36 ✓	Final results Phase I NOX-A12	Proof-of-mechanism Phase II NOX-A12	Proof-of-concept Phase II NOX-A12
Interim data Phase I NOX-E36 ✓	Start Phase II NOX-A12	Proof-of-mechanism Phase II NOX-E36	Start Phase II (with partners) NOX-E36
Start Phase I NOX-A12 ✓	Start Phase Ib / IIa NOX-E36 (healthy volunteers & patients)	Start & final results Phase I NOX-H94	Proof-of-concept Phase II NOX-H94
Finalize Phase I NOX-E36 ✓		Start Phase II NOX-H94	

SENIOR MANAGEMENT

Iain Buchanan

Chief Executive Officer

Dr. Sven Klussmann

Chief Scientific Officer

Dr. Aram Mangasarian

Chief Business Officer

Dr. Heike Balzer

Senior Vice President, Finance

Dr. Dirk Eulberg

Vice President, Project Management

Dr. Frank Fiegert

Vice President, Clinical Drug Development

Dr. Martin F. Humphrey

Vice President, Preclinical Drug Development

Karen Christine Ophoff

Vice President, Legal Affairs, General Counsel

Dr. Axel Vater

Senior Director, Head of Drug Discovery

Dr. Stefan Vonhoff

Vice President, CMC

SUPERVISORY BOARD

Dr. Walter Weninger

Chairman of the Supervisory Board

BUSINESS DEVELOPMENT

NOXXON Pharma Inc.

Dr. Steffen Helmling

Executive Vice President, Business Development

FINANCIAL SUMMARY

In 2007 NOXXON completed a EURO 37 million Series C financing round. The investment was led by TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, and Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft (DEWB). Additional investors included Sevenure Partners, Dow Venture Capital, Dieckell Group, FCP OP MEDICAL BioHealth-Trends, IBG Risikokapitalfonds, VC Fonds Berlin, and others.

PRODUCTS FOR CLINICAL DEVELOPMENT

NOXXON focuses on the development of Spiegelmers for the treatment of inflammatory diseases and hematological disorders. NOXXON's projects are characterized by highly promising targets and clear clinical objectives. Each project addresses a significant unmet medical need.

Spiegelmer NOX-E36, an inhibitor of Monocyte Chemoattractant Protein-1 (MCP-1) is NOXXON's clinical candidate for the treatment of diabetic kidney disease and other complications of type 2 diabetes. In a Phase I clinical trial, NOX-E36 showed excellent safety and pharmacokinetic properties. Pharmacodynamic evaluation revealed a dose-dependent effect on blood monocytes, consistent with the mode of action of NOX-E36. After having successfully completed the first clinical study, multiple dose studies in healthy volunteers and non-insulin dependent diabetic patients with multiple complications will be performed in 2010.


Spiegelmer NOX-A12, NOXXON's second clinical candidate specifically antagonizes Stromal Cell-Derived Factor-1 (SDF-1). SDF-1 binds with high affinity to the chemokine receptors CXCR4 and CXCR7. The CXCR4/SDF-1 axis has been shown to play a role in stem cell mobilization, vasculogenesis, tumor growth and metastasis. Thus, NOX-A12 has the potential to be developed for acute as well as chronic indications in the area of stem cell transplantation, hematological malignancies and/or solid tumors.

The first-in-human clinical trial for NOX-A12 has been successfully completed in May 2010. This Phase I study was designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy individuals following intravenous administration of NOX-A12. Final data analysis demonstrated an excellent safety and tolerability and revealed a long lasting and dose dependent mobilization of WBC and hematopoietic stem cells. NOXXON plans to start a multiple dose Phase I clinical trial by the mid of 2010. The Phase II program will commence late in 2010.

Spiegelmer NOX-H94 is NOXXON's preclinical candidate for the treatment of anemia of inflammation, a common form of anemia associated with many chronic diseases. This Spiegelmer binds an innovative target centrally involved in iron homeostasis. NOX-H94 is currently undergoing final pre-clinical profiling.

In addition, NOXXON has generated Spiegelmers for out-licensing in other disease areas including metabolic syndrome and cancer.

PIPELINE



CORPORATE HEADQUARTERS

NOXXON Pharma AG

Max-Dohrn-Strasse 8-10
10589 Berlin
Germany

Phone: +49 30 726 247 0
FAX: +49 30 726 247 225
Web: www.noxxon.com

BUSINESS DEVELOPMENT

NOXXON Pharma Inc.

Dr. Steffen Helmling
One Broadway, 14th floor
Cambridge, MA 02142
USA

Phone: +1 617 475 1605
FAX: +1 617 475 6099
Email: shelmling@noxxon.com

GENERAL AND MEDIA CONTACT

Emmanuelle Delabre

Phone: +49 30 726 247 100
FAX: +49 30 726 247 225
Email: edelabre@noxxon.com

The sole purpose of this fact sheet is to describe the business activities of NOXXON Pharma AG ("the Company"). This document does not itself constitute or form part of an offer of, or an invitation to purchase any shares in the Company. Neither this document nor any part of it nor the fact of its distribution forms the basis of, or should be relied on in connection with, any contract for the purchase of any shares or for any purpose whatsoever. The Company has not authorized any person to provide third parties with any information, or to make any representation, concerning the offering of any shares in the Company. The delivery of this document shall not under any circumstances imply that information contained herein is correct as at any time subsequent to the date hereof or that there has been no change in the affairs of the Company since the date hereof. No representation or warranty, expressed or implied, is given as to the accuracy of the information or opinions contained in this document and no liability is accepted for any such information or opinion.

Status September 2010